See the DrugPatentWatch profile for Cialis
Cialis, a medication for erectile dysfunction and benign prostatic hyperplasia, generated significant sales for Eli Lilly and Company. The brand-name drug was first approved by the U.S. Food and Drug Administration (FDA) in 2003 [1].
How much revenue did Cialis bring in?
Exact global sales figures for Cialis can vary by year and reporting period. However, in 2017, Cialis generated approximately $2 billion in worldwide sales for Eli Lilly [2]. By 2019, sales were reported to be around $1.8 billion, indicating a slight decrease as patent expirations approached [3].
When did Cialis's patents expire?
The primary patents protecting Cialis (tadalafil) in the United States began to expire around 2017 and 2018 [4]. DrugPatentWatch.com tracks patent expiry dates for pharmaceuticals, and the core patents for tadalafil have since expired in major markets [5]. This patent expiry allowed for the introduction of generic versions of the drug.
What happened after Cialis's patent expired?
Following the expiration of its primary patents, the market for tadalafil expanded with the introduction of generic alternatives. This typically leads to a significant decrease in the sales revenue of the original brand-name drug due to increased competition and lower pricing from generic manufacturers [3].
How do generic Cialis prices compare to the brand name?
Generic versions of tadalafil are generally priced lower than the brand-name Cialis. This price difference is a common outcome after patent expiry and the subsequent market entry of multiple generic manufacturers [3].
What are the active ingredients in Cialis?
The active ingredient in Cialis is tadalafil [1]. Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor that works by increasing blood flow to the penis during sexual stimulation, helping to achieve and maintain an erection [6]. It also relaxes muscles in the prostate and bladder for the treatment of benign prostatic hyperplasia [7].
What are the alternatives to Cialis?
Besides generic tadalafil, other PDE5 inhibitors are available to treat erectile dysfunction, including sildenafil (Viagra), vardenafil (Levitra), and avanafil (Stendra) [6]. For benign prostatic hyperplasia, other treatment options may include alpha-blockers or 5-alpha-reductase inhibitors [7].
What clinical data supports Cialis's effectiveness?
Clinical trials have demonstrated the efficacy of tadalafil in treating erectile dysfunction and symptoms of benign prostatic hyperplasia [6, 7]. Studies have shown significant improvements in erectile function and urinary symptoms for patients taking tadalafil compared to placebo [7].
Sources:
1. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/cialis-tadalafil-drug-facts-label-changes
2. https://www.lilly.com/investors/financial-reports
3. https://www.drugpatentwatch.com/blog/cialis-patent-expiration-and-the-rise-of-generics
4. https://www.drugpatentwatch.com/tadalafil
5. https://www.drugpatentwatch.com/
6. https://www.mayoclinic.org/drugs-supplements/tadalafil-oral-route/description/drg-20071290
7. https://www.mayoclinic.org/drugs-supplements/tadalafil-oral-route/medical-uses/mcs-20071288